Retatrutide Dosing: What Phase 2 Trials Used and What Researchers Should Know

Retatrutide is in active Phase 3 clinical trials as of 2026. The foundational dosing data for the compound comes primarily from the Phase 2 trial published in the New England Journal of Medicine in 2023. That trial used multiple dose cohorts with a structured escalation protocol, providing a detailed picture of how dose relates to both efficacy and tolerability.

The Phase 2 Trial Dose Structure

The Phase 2 trial tested retatrutide at multiple doses in a dose-escalation design. The key dose groups were 1mg, 4mg, 8mg, and 12mg, all administered once weekly by subcutaneous injection. The trial included a placebo group for comparison. Not all doses were escalated immediately. Participants began at lower doses and escalated over a defined period to their target dose, a protocol designed to minimize gastrointestinal side effects during the adjustment phase.

What Each Dose Produced

The 1mg dose showed modest effects relative to placebo, with average weight loss of approximately 8.7% at 48 weeks. The 4mg group showed greater weight loss, averaging approximately 17.3%. The 8mg group averaged approximately 22.8%. The 12mg group achieved the headline result of approximately 24.2% average weight loss at 48 weeks. These figures represent averages across participants who completed the trial, and individual results varied.

The Escalation Protocol

Dose escalation in the trial was gradual to allow gastrointestinal tolerance to develop. Participants in the higher dose groups did not start at 12mg. They moved through lower dose stages over several weeks before reaching the target dose. This is consistent with escalation protocols used for semaglutide and tirzepatide, which also start low and increase over months.

The escalation approach is important for researchers to understand because the timeline to full-dose effects is extended by the escalation period. The 24% weight loss figure at 48 weeks includes the time participants spent at sub-maximal doses. Researchers should factor this into observation window design.

Side Effects by Dose

Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) were dose-dependent in the trial. The highest dose group had the highest rate of GI adverse events, most of which were mild to moderate and concentrated during dose escalation. The trial also documented a modest increase in heart rate, particularly at higher doses. This finding is being closely monitored in Phase 3.

How Retatrutide Dosing Compares to Semaglutide and Tirzepatide

Semaglutide for weight management is approved at a maximum dose of 2.4mg weekly, reached through a 16-week escalation from 0.25mg. Tirzepatide for obesity is approved at a maximum of 15mg weekly, reached over several months from 2.5mg. Retatrutide's trial doses span a different range due to its different potency and mechanism. Direct dose comparisons between compounds are not meaningful because each has a different receptor affinity and efficacy profile.

What Phase 3 Will Tell Us

The ongoing Phase 3 trials are expected to confirm efficacy at the doses tested in Phase 2, characterize the safety profile in larger and more diverse populations, and examine outcomes like cardiovascular events, which were secondary endpoints in Phase 2. The Phase 3 data will be the primary basis for any regulatory approval decision.

Werner Science carries research-grade retatrutide for use in research protocols. Browse their catalog at wernerscience.com/?ref=bwmucbwp and use code SAVE10 for a discount.